Invesco Ltd. Oric Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 22,082 shares of ORIC stock, worth $182,176. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,082

Previous 22,620 2.38%

Holding current value

$182,176

Previous $159,000 42.14%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$7.52 - $11.9 $4,045 - $6,402	-538 Reduced 2.38%	22,082 $226,000
Q2 2024 Aug 13, 2024	SELL	$6.63 - $12.93 $3.13 Million - $6.1 Million	-471,548 Reduced 95.42%	22,620 $159,000
Q1 2024 May 14, 2024	BUY	$8.04 - $16.03 $1 Million - $2 Million	124,946 Added 33.84%	494,168 $6.79 Million
Q4 2023 Feb 12, 2024	BUY	$5.41 - $9.43 $149,775 - $261,069	27,685 Added 8.11%	369,222 $3.4 Million
Q3 2023 Nov 13, 2023	SELL	$6.05 - $9.28 $376,521 - $577,540	-62,235 Reduced 15.41%	341,537 $2.07 Million
Q2 2023 Aug 11, 2023	BUY	$4.95 - $8.4 $2 Million - $3.39 Million	403,772 New	403,772 $3.13 Million
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.07 $32,850 - $86,020	-12,167 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.54 - $16.1 $712 - $2,527	157 Added 1.31%	12,167 $65,000
Q4 2021 Feb 14, 2022	SELL	$12.01 - $20.3 $18,207 - $30,774	-1,516 Reduced 11.21%	12,010 $176,000
Q3 2021 Nov 15, 2021	BUY	$15.9 - $25.22 $27,793 - $44,084	1,748 Added 14.84%	13,526 $282,000
Q2 2021 Aug 17, 2021	BUY	$17.37 - $25.34 $204,583 - $298,454	11,778 New	11,778 $209,000

Others Institutions Holding ORIC

# of Institutions

124

Shares Held

66.6M

Call Options Held

7.8K

Put Options Held

700

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $327M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account